Plan de cuenta de Danone
Líder mundial en alimentación y salud
De un vistazo
Danone es un grupo alimentario francés de lácteos, productos vegetales, nutrición especializada y aguas, con 27.283 M€ de ventas en 2025 y 88.670 empleados.
La misión de Danone es llevar la salud a través de la alimentación al mayor número de personas posible, mediante tres categorías: Essential Dairy & Plant-Based, Nutrición Especializada (leche infantil y nutrición médica) y Aguas. Sus marcas incluyen Activia, Actimel, Oikos, Alpro, Silk, Aptamil, Nutricia, evian y AQUA, vendidas a través de cadenas minoristas, comercio tradicional, comercio electrónico, consumo fuera del hogar y canales especializados como hospitales y farmacias. En 2025, las ventas fueron de 27.283 M€ (+4,5% a perímetro comparable), el resultado operativo recurrente de 3.665 M€ (margen del 13,4%) y el beneficio neto atribuible al grupo de 1.825 M€. Tenía 88.670 empleados a 31 de diciembre de 2025 y 151 centros de producción. Gilles Schnepp preside el Consejo y Antoine de Saint-Affrique es el CEO.
Unidades de negocio
Essential Dairy & Plant-Based (EDP)
48% de las ventas de 2025 (13.158 M€)Yogures, creaciones de café, postres y bebidas y alternativas vegetales bajo Activia, Actimel, Danone, Oikos, YoPro, Alpro y Silk. El crecimiento de 2025 fue de +3,5% a perímetro comparable con un margen del 8,5%; los productos ricos en proteínas, el Skyr y el Kéfir crecen a doble dígito mientras se reorienta Norteamérica. Las ventas del 1S 2026 fueron de 6.681 M€ con el margen bajando al 7,1% porque la inflación superó a los precios.
Nutrición Especializada
34% de las ventas de 2025 (9.277 M€)Leche infantil, alimentación complementaria y nutrición médica pediátrica y de adultos (Aptamil, Nutricia, Neocate, Fortimel, Nutrison, Kate Farms), vendidas en parte a través de hospitales y farmacias. Creció +7,4% a perímetro comparable en 2025 con un margen del 21,7%, el más alto de las categorías; las ventas del 1S 2026 fueron de 4.730 M€. Dirigida por Jean-Marc Magnaudet, presidente de Nutrición Especializada.
Aguas
18% de las ventas de 2025 (4.848 M€)Aguas naturales, aromatizadas y funcionales bajo evian, Volvic, AQUA, Mizone y Bonafont. El crecimiento de 2025 fue de +1,9% a perímetro comparable con un margen del 10,9%; las ventas del 1S 2026 fueron de 2.525 M€ con un margen del 13,3%, con Mizone débil en China.
Zona EMEA
6.133 M€ de ventas en el 1S 2026Europa, Turquía, Oriente Medio, África y CEI, la mayor zona desde la reorganización de enero de 2026. El crecimiento del 1S 2026 fue de +2,1% a perímetro comparable con un margen del 10,4% pese a la retirada de leche infantil. Presidente: Pablo Perversi.
Zona Américas
4.688 M€ de ventas en el 1S 2026Norteamérica y Latinoamérica, incluida la plataforma estadounidense de nutrición médica creada con Kate Farms. El crecimiento del 1S 2026 fue de +3,9% a perímetro comparable con un margen del 9,6%; la reorientación de yogures, cremas para café y productos vegetales en Estados Unidos está en marcha. Presidente: Henri Bruxelles.
Zona APAC
3.116 M€ de ventas en el 1S 2026China, Japón, Australia, Nueva Zelanda, Indonesia, Tailandia, Vietnam e India, con dos tercios en Nutrición Especializada. El crecimiento del 1S 2026 fue de +5,6% a perímetro comparable con un margen del 24,7%. Presidente: Bruno Chevot.
Prioridades estratégicas
- Renovar Danone Chapter 2
- Reorientar las categorías (del yogur a la salud intestinal y las proteínas, de lo vegetal a lo «plant-powered», de las aguas a la hidratación saludable), ampliar modelos de negocio como el consumo en el hogar y fuera del hogar, y expandirse en Estados Unidos, India y el Sudeste Asiático.
- Modelo financiero a medio plazo
- Para 2025-2028: crecimiento de las ventas del 3-5% a perímetro comparable, resultado operativo recurrente que crece más rápido que las ventas, un ROIC estructuralmente de doble dígito y avances hacia 3 mil millones de euros de flujo de caja libre sostenible. La previsión de 2026 se sitúa en ese rango.
- Arreglar Norteamérica
- Añadir capacidad de yogur línea por línea en 13 fábricas, relanzar Activia en el 2S 2026, entrar en el kéfir en Estados Unidos y relanzar la marca Dannon con un nuevo enfoque del yogur griego a principios de 2027, mientras Silk pasa al modelo de Alpro.
- Escalar la nutrición médica
- Kate Farms con Nutricia forma una plataforma estadounidense de nutrición médica de 500 millones de dólares; en China, Danone apunta a una mayor penetración hospitalaria más allá de las ciudades de nivel 1.
- Canales estratégicos e IA
- Los canales ajenos a la gran distribución superan el 50% de las ventas y crecen de 2 a 3 veces más rápido; la IA se despliega desde Microsoft Copilot para todos hasta la cadena de suministro, la I+D y la relación con los minoristas.
Últimos resultados
En el 1S 2026 (seis meses hasta el 30 de junio de 2026), las ventas fueron de 13.936 M€, un 3,5% más a perímetro comparable y un 1,4% en datos reportados, con un crecimiento comparable del 4,2% en el 2T. El resultado operativo recurrente subió un 2,3% hasta 1.854 M€ y el margen al 13,3% (+12 pb), ya que la productividad de los costes generales compensó la retirada de leche infantil y los primeros efectos inflacionistas del conflicto de Oriente Medio. El beneficio neto atribuible al grupo subió un 13,0% hasta 1.175 M€. El flujo de caja libre bajó a 852 M€ desde 1.172 M€ porque Danone constituyó existencias de seguridad, y la deuda neta subió a 8.975 M€. Se confirmó la previsión para 2026 de un crecimiento comparable del 3% al 5% con un resultado operativo recurrente que crece más rápido que las ventas.
Inversiones y operaciones
- Kate Farms
- Participación del 96% adquirida el 1 de julio de 2025 por 839 M€ (983 millones de dólares), una marca estadounidense de nutrición médica y cotidiana de origen vegetal que entra en el perímetro comparable a partir del 3T 2026.
- Huel
- Acuerdo definitivo del 23 de marzo de 2026 para adquirir la marca de nutrición completa con fuertes ventas directas al consumidor en Reino Unido, Europa y Estados Unidos; cierre previsto en el 2S 2026.
- MADE Group y la empresa conjunta láctea australiana
- Acuerdo del 22 de junio de 2026 para comprar MADE Group, con sede en Melbourne (más de 300 M€ de ventas), y el 49% restante de Danone Saputo Dairy Australia, que juntos añadirían más de 400 millones de euros de ventas en APAC.
- Empresa conjunta en Argentina y desinversiones
- Un acuerdo del 24 de marzo de 2026 con Arcor combina Danone Argentina con Mastellone Hermanos en una empresa de gobierno conjunto; Proviva y Lunnarp en Suecia se vendieron el 2 de marzo de 2026.
- Capex de capacidad
- El capex fue de 1.055 M€ en 2025 y 414 M€ en el 1S 2026, para capacidad de productos ricos en proteínas y de nutrición médica, y podría subir al 4,5% de las ventas.
Retos y riesgos
- Retirada de leche infantil
- La retirada de enero de 2026 en Europa y Oriente Medio costó 42 M€ de costes no recurrentes en el 1S 2026 y ha dado lugar a reclamaciones en varias jurisdicciones; Europa sigue siendo un panorama mixto.
- Conflicto de Oriente Medio e inflación de costes
- El conflicto altera la logística en la región y encarece la energía, el transporte, los envases y algunas materias primas; el margen de EDP bajó 68 pb en el 1S 2026 antes de las subidas de precios.
- Competitividad de EDP en Estados Unidos
- El CEO ha manifestado su insatisfacción con partes de la cartera de EDP en Norteamérica: cremas para café, productos vegetales (Silk) y yogures sin proteínas privados de capacidad.
- Dependencia de China
- China supone cerca del 12% de las ventas y es el mayor contribuyente al beneficio, y la leche infantil que se vende allí se fabrica sobre todo en el extranjero; Mizone lastró el 2T 2026.
Lo que dice la dirección
“the food industry is at a tipping point and health through food has never been more relevant”
“It is clear that in the US, our performance in 2025 didn't meet our expectations. We are not where we should be, and we know we need to step up our game.”
“Protein is here to stay. Penetration of GLP-1 is still nowhere”
“volume, volume, volume and mix will remain our priority number one”
Dónde puede ayudar un proveedor
- Resiliencia de la cadena de suministro
- Las existencias de seguridad constituidas frente a las perturbaciones de Oriente Medio y los mayores costes de envases y energía hacen relevantes a los proveedores de planificación del suministro, aprovisionamiento y optimización logística.
- Aumento de capacidad en Estados Unidos
- La reorientación de Norteamérica depende de añadir capacidad de yogur línea por línea en 13 fábricas: los proveedores de equipos, automatización y sistemas de ejecución de la fabricación encajan en esta prioridad.
- Venta directa y marketing de comunidad
- Huel aporta capacidades de venta directa al consumidor y de comunidad que Danone dice que le faltan; las herramientas de comercio electrónico, contenidos y gestión de comunidades pueden apoyar la integración y el impulso a los canales estratégicos.
- Alcance en el canal sanitario
- Escalar la nutrición médica a través de hospitales, farmacias y profesionales sanitarios en Estados Unidos y China requiere socios de capacitación de ventas médicas, economía de la salud y relación con profesionales sanitarios.
Lectura de Tamtam de las prioridades y los retos anteriores, no palabras de la propia empresa.
¿Vendes a empresas como Danone?
Tamtam encuentra las empresas que encajan con tu cliente ideal, investiga cada cuenta y te dice a quién contactar y cuándo.
Encontrar empresas similaresDocumentos clave
Leídos íntegramente por Tamtam; cada resumen enlaza al documento original.
- Universal Registration Document 2025 (Annual Financial Report)
- Danone is a health-focused food group with three categories: Essential Dairy & Plant-Based (EDP, 48% of 2025 sales, €13,158m), Specialized Nutrition (infant formula and medical nutrition, 34%, €9,277m) and Waters (18%, €4,848m). It is no. 1 worldwide in fresh dairy and in plant-based foods and beverages, no. 2 in packaged waters and early life nutrition, no. 4 in adult medical nutrition. 88,670 employees and 151 production sites at end 2025.
- FY2025: sales €27,283m, +4.5% like-for-like (volume/mix +2.7%, price +1.8%) but -0.3% reported after a -5.0% currency effect; recurring operating income €3,665m, margin 13.4% (+44 bps); recurring EPS €3.80 (+4.6%); free cash flow €2,799m; ROIC 10.7% (+62 bps); dividend €2.25 (+4.7%). Reported net income fell 9.7% to €1,825m because of €725m of non-recurring costs (transformation projects in Europe and Indonesia, impairments).
- Growth by zone (LFL): Europe +2.3% (36% of sales), North America +2.0% (23%, "softer growth"), China, North Asia & Oceania +11.7% (14%, entirely volume/mix), Latin America +6.0%, Asia-Middle East-Africa +5.6%. By category: EDP +3.5% (margin 8.5%), Specialized Nutrition +7.4% (margin 21.7%, +112 bps), Waters +1.9% (margin 10.9%).
- The United States is the largest country (20% of sales), China second (12%, and the largest profit contributor); the top-5 markets are 51% of sales. The top ten customers are about 20% of sales, the top five about 14%. Channels outside mass retail (pharmacies, hospitals, homecare, away-from-home, e-commerce) are now over 50% of sales and grew 2-3x faster than mass retail in 2025.
- Strategy: "Renew Danone" Chapter 2 (since June 2024) pivots categories towards protein and gut health, broadens business models (away-from-home, medical nutrition, homecare), expands in the US, India and South-East Asia, and moves "to the front foot" on M&A. Mid-term guidance 2025-2028: 3-5% LFL sales growth, recurring operating income growing faster than sales, structurally double-digit ROIC, long-term ambition of €3bn free cash flow.
- 2025 M&A: 96% of Kate Farms (US plant-based medical nutrition, no. 1 doctor-recommended) for €839m ($983m) on July 1, 2025, creating a US medical nutrition platform; The Akkermansia Company (biotics, Belgium); disposal of the Iranian dairy business (€77m loss); sale of Proviva/Lunnarp (Sweden) signed. Capex rose to €1,055m, mostly capacity for high protein and medical nutrition.
- Organisation: from January 1, 2026 Danone runs three zones (EMEA, Americas, APAC) instead of five; Shane Grant (Deputy CEO, CEO Americas) left in June 2025. Early 2026 events: targeted recall of infant formula batches (January 23, 2026) and consolidation of the Australian dairy JV with Saputo at 51% (February 12, 2026).
- Main risks rated "strong": over-reliance on principal markets (notably China, where infant formula sold is mostly made abroad), packaging/plastics regulation, fast changes in consumer preferences, raw material and energy price volatility (materials are ~75% of COGS, about €10bn a year), climate change. Medium: retail shift (discounters, private label), currency, legal/regulatory, cybersecurity, food safety, talent, business transformation.
- 2026 guidance: like-for-like sales growth of 3% to 5% with recurring operating income growing faster than sales. CEO Antoine de Saint-Affrique: "there is more to do and some areas still require further progress."
- 2026 Interim Financial Report (six months ended June 30, 2026)
- H1 2026 sales €13,936m, +3.5% like-for-like (volume/mix +1.7%, price +1.8%), +1.4% reported with a +0.7% scope effect (Kate Farms, Australian dairy JV) and -3.3% from currencies.
- Recurring operating income €1,854m, margin 13.3% (+12 bps): strong productivity gains including +84 bps in overheads offset a -54 bps fall in margin from operations (infant formula recall in EMEA, first effects of inflation) and -25 bps of reinvestment in A&P, product superiority and capabilities.
- New three-zone reporting: EMEA €6,133m (+2.1% LFL, margin 10.4% flat), Americas €4,688m (+3.9%, margin 9.6%, +31 bps), APAC €3,116m (+5.6%, margin 24.7%). By category: EDP €6,681m (+3.6%, margin 7.1%, -68 bps), Specialized Nutrition €4,730m (+3.2%, margin 22.1%), Waters €2,525m (+3.6%, margin 13.3%, +196 bps).
- Recurring EPS €1.92 (+0.9%); reported net income group share €1,175m (+13.0%), helped by a €122m remeasurement gain on the Australian JV; non-recurring operating expense -€161m (transformation projects €82m, recall costs €42m).
- Free cash flow €852m (vs €1,172m): capex up to €414m and a -€567m working capital outflow from security stocks built up because of the Middle East situation. Net debt €8,975m (+€544m since December); €1.6bn triple-tranche bond issued in March; dividend of €2.25 paid in May (€1,440m).
- Deals signed and pending close in H2 2026: acquisition of Huel (complete nutrition, UK/Europe/US, direct-to-consumer), acquisition of MADE Group (Australia, >€300m sales, high-protein RTD, gut-health yogurts, coconut products) and of the remaining 49% of the Saputo dairy JV, and a dairy joint venture with Arcor in Argentina that deconsolidates Danone Argentina (assets held for sale €240m).
- Risks: no new risk factors, but the Middle East conflict that began in February 2026 is disrupting logistics and inflating energy, transport, packaging and some agricultural costs; the January 2026 infant formula recall has triggered claims in several jurisdictions, with no provision booked.
- 2026 guidance confirmed: like-for-like sales growth of 3% to 5% with recurring operating income growing faster than sales.
- H1 2026 results conference call transcript (CEO Antoine de Saint-Affrique, CFO Juergen Esser)
- Q2 2026 like-for-like sales +4.2% (volume/mix +1.9%, positive in every region and category), reported +4.4% to €7.2bn with scope +0.8% (Kate Farms, Australian JV) and currency -1%; H1 LFL +3.5%, recurring operating margin 13.3% (+12 bps), recurring EPS €1.92 (+0.9%), free cash flow €0.9bn.
- Q2 by category: EDP +3.8%, Specialized Nutrition +4.5% (medical nutrition strong everywhere; infant formula in Europe and the Middle East recovering since mid-Q2), Waters +4.7% (Volvic, Aqua Indonesia). By zone: EMEA +3.6%, Americas +4.3% (North America +2.6%), APAC +5.2% (Mizone down in a soft Chinese waters season).
- Growth engines: high protein double-digit in all regions, Skyr and Kefir double-digit in Europe, Alpro high single-digit, medical nutrition brands Nutrison, Fortimel and Neocate high single to double-digit; away-from-home, hospitals, pharmacies and home care grow 2-3x faster than mass retail.
- North America EDP: "still only at the beginning of the journey"; yogurt lines come on stream line by line through 2026, Activia relaunch in H2, Oikos new formats, International Delight renovation in 2027, Silk repositioned as "plant-powered" with protein yogurt and shakes; creamers have stabilised; "everything that is protein is absolutely absolutely flying".
- M&A under three filters (strategic fit, financial discipline with double-digit ROIC, execution capability): Huel (premium complete nutrition, direct-to-consumer and community skills, 300-400 digital assets a month), MADE Group plus the rest of the Australian JV (doubles APAC EDP, adds more than €400m of sales, accretive to margin and EPS from year one), Argentina JV with Arcor (deconsolidates, EPS-accretive over time); all closing in H2 2026.
- Margin: EDP margin down about 70 bps in H1 because inflation (energy, packaging) arrived before pricing; selective price increases roll out in Q3; hedging protects Specialized Nutrition and Waters more than dairy. Inventory rose about 250 million as security stocks against Middle East supply disruption, to unwind in the coming quarters; capex up €40-50m for medical nutrition and high protein.
- China: infant formula market "normalizing" after the Year of the Dragon, shares gaining via Essensis premiumisation; super-premium Nuturis launching in mainland China after Hong Kong; medical nutrition (tube feeding leadership, pediatrics, oral nutrition) "only at the start of the journey"; volume-based procurement is "business as usual".
- 2026 guidance confirmed: 3-5% LFL growth, recurring operating income faster than sales; no margin guidance ("our guidance is our guidance is our guidance").
- FY 2025 results conference call transcript (CEO Antoine de Saint-Affrique, CFO Juergen Esser)
- 2025, the first year of Renew Danone Chapter 2: like-for-like sales +4.5% with volume/mix +2.7%, recurring operating margin 13.4% (+44 bps, margin from operations +77 bps), recurring EPS €3.80 (+4.6%), free cash flow €2.8bn, ROIC 10.7% (+62 bps), dividend €2.25 (+5%); Q4 LFL +4.7%. Reported sales flat at €27.3bn after -4.4% currency.
- The call opened on the January 2026 infant formula recall (batches in Europe and the Middle East, under new authorities' requirements on cereulide): "food safety and quality are ... our top priority"; no significant stock returns, but shelf disruption at European retailers expected to cost 0.5-1% of group sales in Q1 2026, normalising in March; no products sold through official channels in China affected.
- Growth engines: Oikos Pro exceeded €1bn of revenue in the US; the Danone brand passed €1bn with high single-digit growth; Alpro is a €1bn platform; Aptamil grew double-digit and doubled in Vietnam; Fortimel and Nutrison form a fast-growing billion-euro medical nutrition platform; specialised channels (pharmacies, hospitals, home care) grew double-digit.
- Zones: Europe +2.3% with nine consecutive quarters of positive volume/mix, margin 12.0%; CNAO +11.7%, entirely volume/mix, margin 29.2%; North America +2.0% and only +0.7% in Q4, margin 11.0% (-39 bps) - "we are not where we should be"; Latin America +6.0%, margin up nearly 3 points to 6.4%; AMEA +5.6%.
- North America fixes: new Americas President Henri Bruxelles and deep leadership change (the head of the Alpro turnaround now runs US categories and creamers), Two Good clean-label creamers, Danimals relaunch, yogurt capacity added line by line; creamers to return to growth from Q2 2026 as comps ease. CEO: "I expect the end of not invented here and rapid movements in the US."
- Kate Farms plus Nutricia is now a $500m US medical nutrition platform growing strong double-digit, entering like-for-like from Q3 2026; the Australian dairy JV with Saputo (YoPRO, Activia, Ultimate, over €100m of revenue) is consolidated at 51%. Japan is a €400m EDP business growing strong double-digit on Oikos and Activia.
- Capex to rise from just under 4% to up to 4.5% of sales for high-protein and medical nutrition capacity; working capital at -10% of sales is "best-in-class". EDP margin target is "double-digit territory" but gross margin gains are being reinvested; whey and lactose inflation weighed on H2 gross margin.
- 2026 guidance: +3% to 5% like-for-like with recurring operating income growing faster than sales - "boringly consistent" since 2022.
- Fireside chat at the dbAccess Global Consumer Conference 2026 (Deutsche Bank) with CEO Antoine de Saint-Affrique and CFO Juergen Esser
- Backdrop unchanged despite the Middle East conflict and the Q1 infant formula recall: "the foods market is at a tipping point. People realize that they are what they eat"; ageing, mobility needs and cancer incidence drive demand. Q1 was "exceptional" but changes nothing in guidance or business model; the organisation is focused on volume/mix growth.
- Productivity is a "competitive edge" that funds reinvestment; pricing in response to inflation will be "as limited as possible and as selective as possible", with no large-scale restructuring ("silent restructuring when we need to"), using the Ukraine-war playbook.
- Mix comes from three sources: category mix (medical nutrition is accretive to growth and gross margin), innovation mix (high protein, Activia variants) and channel mix - hypermarkets went from about 55% of sales five years ago to 45% today, pharmacies carry better mix.
- US yogurt: per-capita consumption is about a third of Europe's; protein is "a trend that is here to stay", pushed by health, US government support for milk protein and GLP-1 access; next trends are gut health, kefir, pre- and probiotics and fibre. The Danone brand, "a bit of a sleeping beauty in the US" since 1942, is a billion-euro platform growing double-digit in Europe and Latin America and "has not been leveraged at all so far in the US". Improvement in North America will be "progressive ... quarter by quarter".
- US plant-based: Silk never got the Alpro repositioning from ingredient-led and anti-milk to benefit-led; new teams since January are deploying the Alpro playbook (the moderator referred to the announced closure of the New Jersey facility), and the CEO expects "progress in the next 12 months". Danone sold its stake in Lifeway but may return to kefir in the US.
- Adult medical nutrition grows high single to double-digit every quarter; Danone is no. 1 in China and Europe, investing in sales forces to reach tier 2-3 hospitals and pharmacies; with Kate Farms Danone has been "buying our route to market in the US". No interest in buying a large US infant formula business because of its liabilities: "ROIC, ROIC, ROIC".
- China infant formula: a market still worth about €20bn ten years on while births fell from 14 million to below 8 million; 1,000 players have become about 500, top three hold about 50% versus 70%+ elsewhere, so consolidation and science-led premiumisation (Essensis, Nuturis) continue; the Year of the Dragon was "a blip".
- ROIC went from 7.5% four years ago to over 10%; Kate Farms and Huel are expected to be EPS-accretive after 12 months. No margin-percentage guidance by design: managing to a KPI "you start cutting advertising, cutting in R&I".
- AI: everyone on Microsoft Copilot in a sandbox; AI in R&D (1,200 ferments), marketing, consumer care (a stool tracker), forecasting; Opole (Poland) is one of the most digital nutrition factories; AI image recognition for store checks; the group is planning reskilling for a decade in which "80% of the jobs would have changed". "We are not at peak protein."
- Fireside chat at an investor conference in Boston (September 8, 2026) with CEO Antoine de Saint-Affrique and CFO Juergen Esser, moderated by Warren Ackerman (Barclays)
- Renew Danone Chapter 2 in the CEO's words: "Danone is only doing one thing. We do health through food to as many people as possible", anchored in science; three moves - pivot how categories are seen (protein: Oikos Pro is $1bn-plus; gut health: Activia back to growth; plant-based to plant-powered: Alpro), broaden reach (large mass retail fell from about 60% of sales to closer to 40%, "the key driver of our resilience") and keep expanding via health-centred acquisitions. "We live in a world of constructive dissatisfaction."
- H2 2026 variables: Kate Farms enters like-for-like, the early-life nutrition recall fades, North America improves progressively; Mizone was a drag in Q2 and probably Q3 in a poor Chinese beverage season while Indonesia was strong. Esser: "very confident to deliver within our guidance in the short, medium and long term"; the CEO: the 3-5% band "gives us the flexibility to do the difficult right rather than the easy wrong".
- North America EDP is about 7% of group sales; capacity comes on "one line after the other" across 13 factories and should be a non-topic in five to six months; the plan is to play "a Danone game": protein in new formats, fibre and pre/probiotics with Activia, kefir in the US "in the coming months", and a revival of the Dannon brand with a new Greek approach at the start of 2027. Capacity takes 12-18 months to build; the CFO is "very bullish" on EDP globally (H1 +3.6%, Europe consistent, Japan and Latin America fast).
- Europe EDP: Activia revival is "a long haul journey" but back to growth on fibre and kefir; kefir will be a $100m-plus platform; Skyr combines naturalness and protein. US plant-based: Silk is being moved towards the Alpro model by a new team; "we need to see progress in a relatively short period of time."
- Infant formula recall: the Middle East bounced back in Q2 to prior distribution and shares; Europe is "a mixed bag" with a slower category and shares won in some countries and lost in others, expected to level out; in China social media drove a shift from international to China label, where Danone plays both.
- China: the infant formula market is still about €20bn with 7-8 million births versus 14 million before; premiumisation, urban penetration and consolidation (top three about 50%) still allow growth; Specialized Nutrition China should return to a mid-single-digit contribution; Danone went from no. 4-5 to co-leader in early life nutrition; Essensis is "probably halfway" to full distribution and Nuturis launches in waves; people over 60 in China will go from 250 million (2023) to 300 million (2030) and 350 million (2040), rebalancing the business towards medical nutrition.
- Early life nutrition is one-third China, one-third Europe, one-third rest of world; the latter grows high single to double-digit, is "very profitable" and 95% Aptamil, with investment in Latin America, the Middle East, India and South-East Asia. India has 23 million births a year: "If you want to be relevant in the long term, you need ... critical mass and presence there", built profitably.
- Margins: COGS inflation (packaging, energy, protein) is real and hard to size; levers are productivity, pricing "as we speak in many, many markets" and above all volume/mix; EDP margin should rise over the next years as pricing lands and North America recovers; the pivot from spoonable to drinkable and now "out of the fridge" (Huel, Alpro Meal to Go, ambient protein shakes) opens "a new, very profitable universe".
- Deals: Kate Farms gives a truly superior product and access to more than 1,500 hospitals; Huel brings a "Hueligans" community, 300-400 ads a month and influencer skills, with Danone adding science and distribution; MADE Group is "a mini-Danone" adding about 400 million in Australia, New Zealand and South-East Asia. The CEO reiterated he is "not interested" in the US part of a particular infant formula target because of legal and factory liabilities and a different business model.
Preguntas sobre Danone
¿Qué hace Danone?
Danone fabrica productos lácteos y vegetales, nutrición infantil y médica, y aguas embotelladas, con marcas como Activia, Oikos, Alpro, Aptamil, Nutricia y evian.
¿Cuáles son los ingresos de Danone?
Las ventas fueron de 27.283 M€ en 2025 y de 13.936 M€ en el 1S 2026, un 3,5% más a perímetro comparable.
¿Cuántos empleados tiene Danone?
Danone tenía 88.670 empleados a 31 de diciembre de 2025.
¿Quién dirige Danone?
Antoine de Saint-Affrique es el CEO, Juergen Esser es el CEO adjunto y director financiero, y Gilles Schnepp preside el Consejo.
¿Cuál es la estrategia de Danone?
Renew Danone Chapter 2 reorienta la cartera hacia categorías de salud como las proteínas, la salud intestinal y la nutrición médica, amplía los canales y se expande en Estados Unidos y los mercados emergentes, con el objetivo de un crecimiento del 3-5% a perímetro comparable.
Redactado por Tamtam a partir de los documentos publicados por la propia empresa, enumerados arriba y leídos íntegramente. Las cifras son las de esos documentos, para los periodos que indican. (2026-11-17)